ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine
Hørsholm, Denmark, January 4, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated proof-of-concept also in HER2-transgenic preventive as well as therapeutic tumor mice models. The vaccine has thus reached a further important pre-clinical milestone. These are very important headline results as the therapeutic vaccine is being developed towards first in human clinical investigations in 2023.The additional topline preclinical results